Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions: non-interventional cohort study JONAS
Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radio...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2022-04-13
|
| In: |
Acta dermato-venereologica
Year: 2022, Jahrgang: 102, Pages: 1-6 |
| ISSN: | 1651-2057 |
| DOI: | 10.2340/actadv.v102.293 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.2340/actadv.v102.293 Verlag, kostenfrei, Volltext: https://medicaljournalssweden.se/actadv/article/view/293 
|
| Verfasserangaben: | Martin Kaatz, Peter Mohr, Elisabeth Livingstone, Michael Weichenthal, Alexander Kreuter, Claudia Pföhler, Ulrike Leiter, Jens Ulrich, Jochen Sven Utikal, Ralf Gutzmer, Rudolf Herbst and Dirk Schadendorf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1881559254 | ||
| 003 | DE-627 | ||
| 005 | 20240307075424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2340/actadv.v102.293 |2 doi | |
| 035 | |a (DE-627)1881559254 | ||
| 035 | |a (DE-599)KXP1881559254 | ||
| 035 | |a (OCoLC)1425215257 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kaatz, Martin |d 1968- |e VerfasserIn |0 (DE-588)12335305X |0 (DE-627)082503648 |0 (DE-576)293671079 |4 aut | |
| 245 | 1 | 0 | |a Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions |b non-interventional cohort study JONAS |c Martin Kaatz, Peter Mohr, Elisabeth Livingstone, Michael Weichenthal, Alexander Kreuter, Claudia Pföhler, Ulrike Leiter, Jens Ulrich, Jochen Sven Utikal, Ralf Gutzmer, Rudolf Herbst and Dirk Schadendorf |
| 264 | 1 | |c 2022-04-13 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.02.2024 | ||
| 520 | |a Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radiotherapy, or for patients with symptomatic metastatic BCC. In order to enhance understanding of the effectiveness, safety and utilization of vismodegib in clinical practice in Germany, a non-interventional study, JONAS, was conducted. A total of 53 patients with locally advanced BCC who initiated treatment with vismodegib between 2016 and 2018 were included in the study, which was embedded in the German ADOReg skin cancer registry. Duration of response, the primary endpoint, was 12.4 months, progression-free survival 32.2 months and overall response rate 77.4%. Most adverse events were mild to moderate. Overall, results confirmed previous findings, demonstrating favourable responses and manageable safety of vismodegib in patients with locally advanced BCC in clinical practice. | ||
| 650 | 4 | |a Effectiveness | |
| 650 | 4 | |a German ADOReg skin cancer registry | |
| 650 | 4 | |a Locally advanced basal cell carcinoma | |
| 650 | 4 | |a Non-interventional study | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Vismodegib | |
| 700 | 1 | |a Mohr, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Livingstone, Elisabeth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weichenthal, Michael |e VerfasserIn |0 (DE-588)140953272 |0 (DE-627)623003848 |0 (DE-576)321514157 |4 aut | |
| 700 | 1 | |a Kreuter, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pföhler, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leiter, Ulrike |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ulrich, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 700 | 1 | |a Gutzmer, Ralf |d 1968- |e VerfasserIn |0 (DE-588)113713371 |0 (DE-627)502213558 |0 (DE-576)289772095 |4 aut | |
| 700 | 1 | |a Herbst, Rudolf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta dermato-venereologica |d Uppsala : Acta Dermato-Venereologica, 1921 |g 102(2022), Artikel-ID adv00695, Seite 1-6 |h Online-Ressource |w (DE-627)302725431 |w (DE-600)1492617-9 |w (DE-576)081952848 |x 1651-2057 |7 nnas |a Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions non-interventional cohort study JONAS |
| 773 | 1 | 8 | |g volume:102 |g year:2022 |g elocationid:adv00695 |g pages:1-6 |g extent:6 |a Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions non-interventional cohort study JONAS |
| 856 | 4 | 0 | |u https://doi.org/10.2340/actadv.v102.293 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://medicaljournalssweden.se/actadv/article/view/293 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240226 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 12 |y j | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 9 | ||
| 999 | |a KXP-PPN1881559254 |e 449106296X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 26.02.2024"],"title":[{"subtitle":"non-interventional cohort study JONAS","title":"Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions","title_sort":"Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions"}],"id":{"doi":["10.2340/actadv.v102.293"],"eki":["1881559254"]},"recId":"1881559254","relHost":[{"pubHistory":["Volume 2, issue 2 (1921) [?]-"],"titleAlt":[{"title":"ActaDV"}],"recId":"302725431","disp":"Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions non-interventional cohort study JONASActa dermato-venereologica","note":["Fortsetzung der Druck-Ausgabe","Volltext auch als Teil einer Datenbank verfügbar","Gesehen am 16.10.24"],"title":[{"subtitle":"a journal for clinical and experimental research in the field of dermatology and venereology","title_sort":"Acta dermato-venereologica","title":"Acta dermato-venereologica"}],"id":{"zdb":["1492617-9"],"eki":["302725431"],"issn":["1651-2057"]},"part":{"extent":"6","year":"2022","pages":"1-6","text":"102(2022), Artikel-ID adv00695, Seite 1-6","volume":"102"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"[1921?]-","publisherPlace":"Uppsala ; Uppsala ; London [u.a.]","publisher":"Acta Dermato-Venereologica ; Medical Journals Sweden AB ; Taylor & Francis"}]}],"person":[{"role":"aut","display":"Kaatz, Martin","given":"Martin","family":"Kaatz","roleDisplay":"VerfasserIn"},{"given":"Peter","display":"Mohr, Peter","role":"aut","family":"Mohr","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Livingstone","role":"aut","display":"Livingstone, Elisabeth","given":"Elisabeth"},{"family":"Weichenthal","roleDisplay":"VerfasserIn","given":"Michael","display":"Weichenthal, Michael","role":"aut"},{"given":"Alexander","display":"Kreuter, Alexander","role":"aut","roleDisplay":"VerfasserIn","family":"Kreuter"},{"family":"Pföhler","roleDisplay":"VerfasserIn","role":"aut","display":"Pföhler, Claudia","given":"Claudia"},{"role":"aut","display":"Leiter, Ulrike","given":"Ulrike","roleDisplay":"VerfasserIn","family":"Leiter"},{"display":"Ulrich, Jens","role":"aut","given":"Jens","family":"Ulrich","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Utikal","given":"Jochen","display":"Utikal, Jochen","role":"aut"},{"display":"Gutzmer, Ralf","role":"aut","given":"Ralf","roleDisplay":"VerfasserIn","family":"Gutzmer"},{"roleDisplay":"VerfasserIn","family":"Herbst","given":"Rudolf","display":"Herbst, Rudolf","role":"aut"},{"given":"Dirk","role":"aut","display":"Schadendorf, Dirk","family":"Schadendorf","roleDisplay":"VerfasserIn"}],"physDesc":[{"extent":"6 S."}],"name":{"displayForm":["Martin Kaatz, Peter Mohr, Elisabeth Livingstone, Michael Weichenthal, Alexander Kreuter, Claudia Pföhler, Ulrike Leiter, Jens Ulrich, Jochen Sven Utikal, Ralf Gutzmer, Rudolf Herbst and Dirk Schadendorf"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"2022-04-13","dateIssuedKey":"2022"}]} | ||
| SRT | |a KAATZMARTIEFFECTIVEN2022 | ||